Head-To-Head Review: Trinity Capital (NASDAQ:TRIN) & Dominari (NASDAQ:DOMH)

Dominari (NASDAQ:DOMH) and Trinity Capital (NASDAQ:TRIN) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Profitability

This table compares Dominari and Trinity Capital’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dominari	-51.61%	-235.37%	-163.66%
Trinity Capital	43.45%	14.94%	6.69%

Risk and Volatility

Dominari has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Trinity Capital has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Insider & Institutional Ownership

42.5% of Dominari shares are held by institutional investors. Comparatively, 24.6% of Trinity Capital shares are held by institutional investors. 55.3% of Dominari shares are held by insiders. Comparatively, 4.3% of Trinity Capital shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Dominari and Trinity Capital, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1	0	0	0	1.00
Trinity Capital	1	1	4	1	2.71

Trinity Capital has a consensus price target of $16.67, indicating a potential downside of 5.38%. Given Trinity Capital’s stronger consensus rating and higher probable upside, analysts clearly believe Trinity Capital is more favorable than Dominari.

Earnings & Valuation

This table compares Dominari and Trinity Capital”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10 million	0.48	-$22.43 million	($5.39)	-0.45
Trinity Capital	$216.31 million	7.71	$135.60 million	$1.75	10.07

Trinity Capital has higher revenue and earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Trinity Capital, indicating that it is currently the more affordable of the two stocks.

Summary

Trinity Capital beats Dominari on 12 of the 15 factors compared between the two stocks.

About Dominari

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

About Trinity Capital

Trinity Capital Inc. is a business development company. It is a venture capital firm specializing in venture debt to growth stage companies looking for loans and/or equipment financing. Trinity Capital Inc. was founded in 2019 is based in Phoenix, Arizona with additional offices in the United States.